<DOC>
	<DOCNO>NCT02967614</DOCNO>
	<brief_summary>To assess pharmacokinetic Interaction Dorzolamide Brimonidine healthy male subject .</brief_summary>
	<brief_title>KJ-TFC-004 Drug-drug Interaction Study</brief_title>
	<detailed_description>Clinical trial evaluate influence drug drug-drug interaction Brimonidine Dorzolamide co-administration pharmacokinetics Brimonidine pharmacokinetics Dorzolamide healthy volunteer</detailed_description>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Healthy male adult age 19 50 screening period BMI 18kg / m2 le 30kg / m2 weight 55kg Signed inform consent form prior study participation . Presence medical history concurrent disease may interfere treatment safety assessment completion clinical study , include clinically significant disorder kidney , liver , cardiovascular system , respiratory system , endocrine system , neuropsychiatric system .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>